Theraxyte
Changping
About Theraxyte
TheraXyte BioScience is a biotechnology company focused on extracellular vesicle (EV)-mediated drug delivery and novel EV-based therapeutics. It aims to establish a multifunctional EV-based drug delivery platform that can meet the upcoming challenges of various therapeutic applications, driving EV research from the lab bench to the bedside, and making a positive impact on human health by overcoming unsolved challenges with novel EV-based therapeutics. TheraXyte has developed and continuously upgraded its EV-based drug delivery platform, TAXY, which could enable the mass production of modifiable EVs at the GMP manufacturing level, has the capability of effectively payload packaging, and target organs/cells of interest where payload drug molecules/active biological molecules could be effectively released as therapeutics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $10.0M
- Funding stage: Seed
- Last round: Seed (Jul 2022)
- Website: theraxyte.com
- Phone: +86 010 8072 2985
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/theraxyte-131353 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.